Arbor Capital Management Inc. ADV Sells 121 Shares of Zoetis Inc. (NYSE:ZTS)

Arbor Capital Management Inc. ADV lessened its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 2.2% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 5,337 shares of the company’s stock after selling 121 shares during the quarter. Arbor Capital Management Inc. ADV’s holdings in Zoetis were worth $921,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. International Assets Investment Management LLC increased its stake in Zoetis by 40.7% during the 4th quarter. International Assets Investment Management LLC now owns 2,429 shares of the company’s stock worth $479,000 after purchasing an additional 703 shares in the last quarter. Aveo Capital Partners LLC bought a new stake in shares of Zoetis during the fourth quarter worth $225,000. Gryphon Financial Partners LLC increased its position in shares of Zoetis by 11.8% during the fourth quarter. Gryphon Financial Partners LLC now owns 3,056 shares of the company’s stock worth $601,000 after acquiring an additional 322 shares in the last quarter. Jump Financial LLC acquired a new stake in shares of Zoetis during the fourth quarter worth $339,000. Finally, Dimensional Fund Advisors LP lifted its position in Zoetis by 6.3% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,766,671 shares of the company’s stock valued at $348,688,000 after acquiring an additional 105,469 shares in the last quarter. 92.80% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on ZTS. Argus upgraded Zoetis to a “strong-buy” rating in a report on Friday, August 9th. Piper Sandler increased their price objective on Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a report on Wednesday, August 14th. Stifel Nicolaus restated a “buy” rating and issued a $200.00 target price on shares of Zoetis in a research note on Tuesday, August 27th. Finally, BTIG Research raised their price target on shares of Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a research note on Monday, August 12th. Nine analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Zoetis presently has an average rating of “Buy” and a consensus price target of $217.11.

Zoetis Trading Up 1.4 %

Shares of NYSE:ZTS opened at $189.23 on Monday. The company has a 50-day simple moving average of $181.22 and a 200 day simple moving average of $174.39. The company has a market capitalization of $85.73 billion, a P/E ratio of 36.46, a price-to-earnings-growth ratio of 2.90 and a beta of 0.88. The company has a debt-to-equity ratio of 1.32, a quick ratio of 2.09 and a current ratio of 3.45. Zoetis Inc. has a 52-week low of $144.80 and a 52-week high of $201.92.

Zoetis (NYSE:ZTS) last issued its earnings results on Tuesday, August 6th. The company reported $1.56 EPS for the quarter, topping the consensus estimate of $1.49 by $0.07. Zoetis had a return on equity of 50.67% and a net margin of 26.29%. The company had revenue of $2.36 billion during the quarter, compared to the consensus estimate of $2.31 billion. During the same period in the previous year, the company posted $1.41 EPS. The firm’s revenue for the quarter was up 8.3% compared to the same quarter last year. Sell-side analysts forecast that Zoetis Inc. will post 5.84 earnings per share for the current year.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.